Chagas Disease Therapeutics Market is estimated to be US$ 14.2 million by 2030 with a CAGR of 7.5% during the forecast period

Download Sample

Published Date: August 2023

The Chagas Disease Therapeutics Market accounted for US$ 6.9 million in 2020 and is estimated to be US$14.2 million by 2030 and is anticipated to register a CAGR of 7.5%. Chagas disease is caused by the parasite Trypanosoma cruzi, which is found in the faeces of the triatomine bug, also known as the kissing bug because it bites people on the face as they sleep. It causes a severe, abrupt illness that lasts a long period. It is passed from mother to foetus during pregnancy, via blood transfusions, and on rare occasions, via organ transplantation. Early signs of Chagas illness include fever, headache, local swelling at the bite site, and swollen lymph nodes. Around half of those bitten by the triatominae bug experience purplish inflammation of an eyelid or skin lesion as their initial symptom.

The report " Global Chagas Disease Therapeutics Market, By Drug type (Nifurtimox and Benznidazole), By Treatment type (Symptomatic treatment and Antiparasitic treatment), By Type (Acute chagas disease and Chronic chagas disease),By Distribution channel ( Hospital pharmacies, Retail pharmacies and Online pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”

Key Highlights:

DAIICHI SANKYO COMPANY, LIMITED and the Medications for Neglected Diseases Initiative (DNDi) announced a research agreement in March 2017 to develop drugs for Chagas disease and leishmaniasis.
The Argentinian National Administration for Drugs, Food, and Medical Technologies (ANMAT) approved benznidazole, a medication developed by Laboratorio Elea Phoenix SA, for paediatric use in the treatment of Chagas disease in April 2018.

Analyst View:

An increase in R&D activities for the development of novel Chagas disease treatments and approval for new products, a rise in the prevalence of Chagas disease due to unsanitary conditions, and an increase in the Chagas disease population are among the factors driving the growth of the Chagas disease treatment market during the forecast period. In recent years, several companies in the chagas disease treatments sector have increased their research activities. The fundamental motivation for this step is to find new therapy alternatives for chagas disease. In addition, a number of vendors have been given permission to launch new products. The market for chagas disease treatment is expanding.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Chagas Disease Therapeutics Market, By Drug type (Nifurtimox and Benznidazole), By Treatment type (Symptomatic treatment and Antiparasitic treatment), By Type (Acute chagas disease and Chronic chagas disease),By Distribution channel ( Hospital pharmacies, Retail pharmacies and Online pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Key Market Insights from the report:

The Global Chagas Disease Therapeutics Market accounted for US$ 6.9 million in 2020 and is estimated to be US$ 14.2 million by 2030 and is anticipated to register a CAGR of 7.5%. The Global Chagas Disease Therapeutics Market is segmented based on the drug type, treatment type, type, distribution channel and region.

By Drug type, the Global Chagas Disease Therapeutics Market is segmented into Nifurtimox and Benznidazole.
By Treatment type, the market is segmented in Symptomatic treatment and Antiparasitic treatment.
By Type, the Global Chagas Disease Therapeutics Market is segmented into Chronic chagas disease and Acute chagas disease.
By Distribution channel, the market is segmented into Hospital pharmacies, Retail pharmacies and Online pharmacies.
By Region, the Global Chagas Disease Therapeutics Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Latin America is the leading region in the Global chagas disease therapeutics market.

Competitive Landscape:

The key players operating in the global chagas disease therapeutics market includes F. Hoffmann-La Roche Ltd., KaloBios Pharmaceuticals, Inc., Johnson & Johnson, ELEA SACIF Laboratory, Bayer AG, Humanigen, Inc, Savant HWP, Inc, Eisai Co., Ltd, Oblita Therapeutics, GlaxoSmithKline plc, Collaborations Pharmaceuticals, Inc, Astellas Pharma Inc, Sanofi, Pfizer Inc, Epichem Pty Ltd, DAIICHI SANKYO COMPANY, LIMITED, Insud Pharma group, Novartis AG, Kancera AB, AstraZeneca, Maprimed S.A. and others

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Some Important Points Answered in this Market Report Are Given Below:

Explains an overview of the product portfolio, including product development, planning, and positioning.
Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies.
Detailed analysis of the market revenue over the forecasted period.
Examining various outlooks of the market with the help of Porter’s five forces analysis, PEST & SWOT Analysis.
Study on the segments that are anticipated to dominate the market.
Study on the regional analysis that is expected to register the highest growth over the forecast period.